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Introduction: The goal of the present work was to examine how clinicians’ perceptions of 
the properties of antidepressants may inﬂ  uence their choice of antidepressants when treating 
major depressive disorder (MDD).
Methods: 273 of 682 (40%) clinicians attending a psychopharmacology review course re-
sponded to a questionnaire designed to explore their practices and perceptions with regards to 
antidepressant pharmacotherapy.
Results: Most clinicians ranked efﬁ  cacy (57.3%) as the most important factor when selecting 
antidepressants, followed by safety (23.0%), tolerability (9.4%), rapidity of action (5.2%), and 
cost (4.9%). However, when presented with hypothetical scenarios in which there was a dif-
ference in efﬁ  cacy between two antidepressant agents, the relative safety, tolerability, and cost 
of the two agents signiﬁ  cantly inﬂ  uenced the likelihood of choosing one antidepressant over 
another. In fact, clinicians required progressively greater differences in efﬁ  cacy between two 
agents in order to select one antidepressant over another given a difference in terms of their 
safety than tolerability, or their tolerability than cost (p < 0.0001 all comparisons).
Conclusions: When selecting an antidepressant, clinicians appear to be most inﬂ  uenced by 
efﬁ  cacy, followed by safety. Rapidity of action and cost may be less salient considerations in 
clinical practice. Further research is necessary to elucidate factors that inﬂ  uence clinicians’ 
choice of antidepressants.
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Introduction
Little is known with regards to which factors inﬂ  uence the antidepressant prescribing 
practices of clinicians when treating patients with major depressive disorder (MDD). 
Unfortunately, existing depression treatment guidelines such as those of the Ameri-
can Psychiatric Association (APA 2000) and of the Agency for Health Care Policy 
and Research (AHCPR- Mulrow et al 1999) do not offer an adequate framework for 
evaluating which treatment options are most efﬁ  cacious. The APA’s revised “Practice 
Guideline for the Treatment of Major Depressive Disorder” (APA 2000), for example, 
concludes that antidepressants appear to be equally effective for the treatment of MDD, 
and thereby suggest that the choice of antidepressants be based on considerations of 
their relative side-effect, safety, and tolerability proﬁ  les as well as their relative cost. 
Nevertheless, subsequent surveys indicate that a substantial proportion of practic-
ing clinicians continue to believe that some antidepressants are more effective than 
others (Petersen et al 2002). In the absence of replicated clinical research guiding the 
choice of antidepressants, it is interesting to examine which factors clinicians take 
into account when selecting one agent over another. While a number of surveys have 
examined factors which inﬂ  uence clinician’s selection of antidepressants (Olfson et al 
1998; Hickie et al 1999; Garrison and Levin 2000; Petersen et al 2002), the majority 
of these reports focus on the presence of various illness characteristics (ie, depressive Neuropsychiatric Disease and Treatment 2007:3(1) 170
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subtypes, neuro-vegetative symptom patterns), little is 
known regarding the role of drug characteristics (ie, efﬁ  cacy, 
rapidity, safety, tolerability, and cost) as factors inﬂ  uencing 
clinicians when choosing among available antidepressants. 
The objective of this study is to gather data from a large 
group of clinicians on how their perceptions of the relative 
properties of antidepressants, including efﬁ  cacy, rapidity 
of action, safety (ie, the likelihood of an antidepressant 
causing serious adverse events), tolerability (ie, the likeli-
hood of treatment with an antidepressant being prematurely 
terminated due to uncomfortable side-effects) and cost, may 
inﬂ  uence their choice of antidepressants.
Method
Clinicians attending the Massachusetts General Hospital 
annual psychopharmacology review course responded to a 
brief, anonymous questionnaire exploring how their percep-
tions of the relative properties of antidepressants inﬂ  uenced 
their choice of antidepressants. The administration of the 
questionnaire was approved by the Massachusetts General 
Hospital Institutional Review Board (IRB). A brief cover 
letter was attached to the questionnaire describing the volun-
tary research survey. No written consent was required. The 
questionnaire had two sections, and required approximately 
5 minutes to complete. The ﬁ  rst section elicited clinician 
responses with regards to their ranking of ﬁ  ve antidepressant 
factors (efﬁ  cacy, safety, tolerability, cost, and rapidity of 
action) inﬂ  uencing their choice of antidepressants. The second 
section contained hypothetical scenarios during which clini-
cians were asked to select the minimal difference in either 
response rates or the rapidity of response that they would 
require in order to chose one agent over another given differ-
ences in either their safety, tolerability, cost, or some combina-
tion of these factors. There were ﬁ  ve possible responses to the 
questions regarding the minimal difference in response rates: 
a) 5%–10%, b) 10%–20%, c) 20%–30%, d) 30%–50%, and 
e) 50%+. There were four possible responses to the questions 
regarding the minimal difference in rapidity of response: a) 1–2 
weeks, b) 2–3 weeks, c) 3–4 weeks, and d) 4+ weeks. 
Statistical tests
Clinician responses to those questions eliciting the mini-
mal difference in response rates between two hypothetical 
antidepressants required in order to select one agent over 
another were ranked from 1 to 5 according to the magnitude 
of the difference in response rates from lowest (5–10%) to 
highest (50% +). Similarly, clinician responses to those 
questions eliciting the minimal difference in rapidity of 
response between two hypothetical antidepressants required 
in order to select one agent over another were ranked from 1 
to 4 according to the magnitude of the difference in rapidity 
of response from lowest (1–2 weeks) to highest (4+ weeks). 
Six (6) Wilcoxon signed rank tests were used to compare dif-
ferences in response rank for each clinician between the four 
scenarios (1: comparable safety and tolerability and cost; 2: 
comparable safety and tolerability only; 3: comparable safety 
and cost only; 4: comparable tolerability and cost only). 
This was then repeated for those questions that substituted 
response rates for the rapidity of response as their outcome. 
We corrected for multiple analyses using the Bonferroni 
method (given a total of 12 analyses, statistical signiﬁ  cance 
was set at p = 0.05/12 = 0.0042 (two tailed) for each test).
Results
Sample characteristics 
Two hundred seventy-three (273) of 682 (40.0%) of clinicians 
attending the course responded to the survey (57.1% 
women, mean age 50.5 ± 9.6 years, completed training 
17.3 ± 10.6 years ago, average 362.1 ± 705.1 patients treated 
per year). The respondent sample was composed largely 
of practicing clinicians, including 72.2% psychiatrists, 
7.3% non-psychiatrist physicians, and 8.8% registered nurses. 
A little over 60% came from the Northeast and Mid-Atlantic 
states with the others representing a national and international 
(8.8%) distribution. 33.0% identiﬁ  ed themselves as having 
special expertise in psychopharmacology, while 52.7% 
identiﬁ  ed themselves as having expertise in both psycho-
pharmacology and psychotherapy.
Ranking of 5 antidepressant properties 
inﬂ  uencing antidepressant selection
When asked to rank 5 factors (efﬁ  cacy, safety, tolerability, 
rapidity, and cost) for their relevance in inﬂ  uencing their deci-
sion-making when selecting an antidepressant, most clinicians 
chose efﬁ  cacy as most relevant (57.3% or 152/265), followed 
by safety (23.0% or 61/265) tolerability (9.4% or 25/265), cost 
(5.2% or 14/265), and rapidity of action (4.9% or 13/265).
Selecting minimal differences in efﬁ  cacy 
as a function of safety, tolerability, and cost
Significant differences were found when we compared 
clinician responses when choosing the minimal difference 
in response rates required in order to select one hypothetical Neuropsychiatric Disease and Treatment 2007:3(1) 171
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antidepressant agent over another. Speciﬁ  cally, clinicians 
required smaller differences in response rates between two 
hypothetical agents with comparable safety, tolerability, 
and cost than two agents that differed in cost, tolerability, or 
safety. These results suggest that all three factors inﬂ  uence 
clinician treatment decisions. Similarly, clinicians required 
smaller differences in response rates between two hypotheti-
cal agents that differed in terms of cost than tolerability, or 
cost than safety. These results suggest that cost was less 
a consideration than either tolerability or safety. Finally, 
clinicians required smaller differences in response rates 
between two hypothetical agents that differed in terms of 
tolerability than safety, suggesting that tolerability was less 
of a consideration than safety. These results were replicated 
when the outcome was changed to the rapidity of response 
(see Tables 1 and 2).
Discussion
The results of our survey reveal interesting ﬁ  ndings on the 
relative role of the ﬁ  ve antidepressant properties examined, 
namely efﬁ  cacy, rapidity of action, safety, tolerability and 
cost, in inﬂ  uencing clinicians’ decision-making when choos-
ing antidepressants. Speciﬁ  cally, when asked to rank which 
of the ﬁ  ve factors they are most likely to take into account 
when selecting one antidepressant over another, most ranked 
efﬁ  cacy as most important followed by safety. Relatively 
few clinicians chose tolerability, rapidity of action, or cost 
as most important. This is of interest, given the fact that, as 
pointed out in recent reviews, several meta-analyses have 
called into question the magnitude of beneﬁ  ts derived from 
antidepressant treatment beyond placebo effects (Walsh et al 
2002; Papakostas and Fava 2006). The emphasis on efﬁ  cacy 
is also interesting given that true differences in efﬁ  cacy across 
classes of antidepressants, although claimed, have been difﬁ  -
cult to establish and there currently exist no reliable estimates 
for the magnitude of these potential inter-class differences 
in clinical settings. In contrast, cost differences, which are 
readily quantiﬁ  able, do not appear to have a similar inﬂ  uence 
over antidepressant prescribing. 
Despite this emphasis on efﬁ  cacy, when presented with 
hypothetical scenarios in which there was a difference in 
efﬁ  cacy between two antidepressant agents, clinicians re-
ported that their relative safety and tolerability proﬁ  les as 
well as their cost were found to signiﬁ  cantly inﬂ  uence their 
choices of one antidepressant over another. In fact, clinicians 
are more strongly inﬂ  uenced in their choice of antidepres-
sants based on perceived differences in the safety proﬁ  le of 
two agents than tolerability, and in perceived differences 
in tolerability than cost.  For example, nearly two thirds of 
clinicians would choose an antidepressant with a 5%–20% 
greater response rate over another provided that these agents 
were comparable with respect to their safety, tolerability 
and cost. Similarly, if these agents were to differ in terms of 
their cost alone, approximately one in ﬁ  ve clinicians would 
choose an agent with a 5%–20% greater response rate over 
another. Given a difference in tolerability proﬁ  le alone, 
however, a little more than one-third of clinicians would 
choose an agent with a 5%–20% greater response rate over 
another agent over another, while approximately only one in 
six clinicians would make the same choice given a difference 
in safety proﬁ  le alone. 
In light of the lack of robust and replicated differences in 
efﬁ  cacy between antidepressants or antidepressant classes, it 
is to be expected that cost, tolerability and, of course, safety 
have a strong inﬂ  uence on clinicians’ decision-making. How-
ever, clinicians’ perceptions regarding efﬁ  cacy do not closely 
reﬂ  ect the literature. For example, nearly 40% of clinicians 
require at least a 50% difference in response rates between 
two antidepressants in order to select the agent with the infe-
rior safety proﬁ  le (ie, selective serotonin reuptake inhibitors 
and monoamine oxidase inhibitors), a staggering number 
given that the mean drug-placebo difference in antidepres-
Table 1 Distribution of clinician responses: “What would be the minimal difference in response rates between two agents required in 
order for you to select one agent over another if those two agents possessed comparable…?”
 5%–10%  10%–20%  20%–30%  30%–50%  50%+
Safety, tolerability, cost*  27.8%  37.2%  23.6%  6.0%  5.2%
Safety, tolerability**  17.2%  35.7%  24.0%  17.2%  5.6%
Safety, cost† 12.7%  21.4%  27.0%  18.7%  19.9%
Tolerability, cost  9.0%  7.1%  21.8%  22.1%  39.4%
Note: *p < 0.0001 when comparing the distribution in response rates between the top (equivalent safety, tolerability, and cost) and bottom three hypothetical scenarios.
**p < 0.0001 when comparing the distribution in response rates between comparable safety/tolerability and comparable safety/cost.
**p < 0.0001 when comparing the distribution in response rates between comparable safety/tolerability and comparable tolerability/cost. 
†p < 0.0001 when comparing the distribution in response rates between comparable safety/cost and tolerability/ cost. Neuropsychiatric Disease and Treatment 2007:3(1) 172
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sant response rates was recently estimated as approximately 
16.8% (Papakostas and Fava 2006). Similar ﬁ  ndings were 
observed when we substituted clinical response with the 
rapidity of response as the main outcome. Almost 50% of 
clinicians responded that they would require a minimum of 
approximately 4 weeks difference in the rapidity of response 
between two antidepressants in order to choose an agent with 
an inferior safety proﬁ  le. However, the development, in the 
near future, of antidepressants that are more effective than 
those currently available by 30%–50% is very unlikely. Nev-
ertheless, smaller advantages in efﬁ  cacy, some argue as small 
as a 10% difference in response rates (Cipriani et al 2006), 
may yield meaningful results in clinical practice. Therefore, 
better educating clinicians about the magnitude and relevance 
of any differences in efﬁ  cacy between antidepressants would 
be necessary in order to ensure that depressed patients fully 
beneﬁ  t from treatment.
One limitation of the present work is in the number of 
clinicians that responded to our questionnaire. Speciﬁ  cally, 
although there were 682 clinicians present at the time the 
questionnaire was administered, only 273 (40.0%) replied. 
Another limitation is the absence of questions that would 
reﬂ  ect various gradients of difference in cost, tolerability 
and safety between two agents. In addition, no clariﬁ  cation 
was made if the agents were to be used as monotherapy or 
adjunctive therapy for depression, as ﬁ  rst-line treatment or 
for treatment-resistant depression, or as an as an alternative 
treatment (switch) following intolerance to a given agent. 
In addition, the present questionnaire was not designed to 
take into account other factors inﬂ  uencing antidepressant 
prescription including patient preference, insurance cover-
age, personal history of response, family history of response, 
neuro-vegetative symptom pattern, psychiatric co-morbidity, 
or medical co-morbidity.
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